Figure 5
Effect of uremic toxins on monocyte subpopulation-platelet aggregation (%). Sodium citrate blood from healthy donors (n = 8) was pre-incubated in the absence and presence of abciximab or anti-CD62P, and incubated for 24 h in the presence of salt control solution (Ctrl), (A) sulfate mixture or (B) thrombine receptor activator peptide (TRAP). Results are presented a mean ± SD. *p < 0.05 vs. Ctrl; #/°p < 0.05 vs. sulfates/TRAP; ##/°°p < 0.005 vs. sulfates/TRAP; °°°p < 0.0005 vs. TRAP. MPA: monocyte-platelet aggregates. CD14++CD16-: classical monocyte-platelet aggregates; CD14++CD16+: intermediate monocyte-platelet aggregates; CD14+CD16++: non classical monocyte-platelet aggregates; CD14+CD16−: CD14+CD16–platelet aggregates.
